Anti-Treponema pallidum antibody (Anti-TP) (Anti-TP)

Anti-Treponema pallidum antibodies are host-produced immunoglobulins, specifically IgG and IgM, generated in response to infection by the spirochete Treponema pallidum, the causative agent of syphilis (StatPearls, 2023). These antibodies target specific protein antigens on the surface of the bacterium and are the primary analytes detected in treponemal diagnostic tests used to confirm infection (CDC, 2021). In clinical practice, these antibodies are used to confirm a syphilis diagnosis following a reactive non-treponemal screening test or as part of a reverse screening algorithm (Mayo Clinic Laboratories, 2023). Because these antibodies often remain detectable for life regardless of treatment status, they serve as a marker of lifetime exposure rather than a measure of current disease activity (PubMed, 2022). They are not targets for pharmacological intervention; rather, the bacterium itself is targeted by antibiotics such as Penicillin G, which inhibits bacterial cell wall synthesis (NIH, 2023). Consequently, these antibodies are classified as diagnostic biomarkers rather than therapeutic targets in the context of infectious disease management.

Other names

Treponemal antibodySyphilis-specific antibodyAnti-T. pallidum IgGAnti-T. pallidum IgMT. pallidum antibody

Not applicable as a therapeutic target; functions as a diagnostic analyte for the detection of syphilis infection.